AstraZeneca Access 360™ Provides Patient Access, Reimbursement Support, and Information about Affordability Programs for AstraZeneca’s Medicines
FDA Approves KEYTRUDA® for Patients with Certain Bladder Cancer
KEYTRUDA® Now approved for Adult and Pediatric Patients with Unresectable or Metastatic MSI-H or dMMR Solid Tumors
FDA Approves IMFINZI™ (durvalumab) for Previously Treated Patients with Bladder Cancer
FDA Approves KEYTRUDA® For Several New Indications
Follow RMOS on Twitter
What's New @ RMOS:
RMOS Submits Letter Regarding Medicare Part B to Department of Health and Human Services
AstraZeneca's TAGRISSO® (osimertinib) Receives FDA Full Approval
View the RMOS 2016 Year in Review!
ACCC Submits Comments to CMS on Part B Drug Proposal
ACCCBuzz Blog: ACCC Voices Part B Demo Concerns on Capitol Hill & at CMS
| ACCC Resources
| ASCO Resources
| ASCO Connection |
© Oncology State Society Network. All rights reserved.